Other

Baxter Healthcare Sa

Baxalta Gmbh

Nanotherapeutics, Inc.

Michael Bergmann

Thomas Muster

Markus Wolschek

Andrej Egorov

Peter M Palese

Julia Romanova

Elisabeth Roethl

Christian Kittel

Enami Masayoshi

The present invention relates to a novel replication deficient influenza virus comprising a modified NS1 segment coding for a NS1 protein lacking a functional RNA binding domain and functional effector domain and having a heterologous sequence inserted between the splice donor site and the splice acceptor site of the NS gene segment. The virus can be used as vector for expression of various proteins like chemokines, cytokines or antigenic structures and to produce vaccines. A fusion peptide comprising part of the N-terminus of an NS1 protein and a signal sequence fused to the C-terminus of said NS1 peptide is also provided.

Replication deficient influenza virus for the expression of heterologous sequences

The present invention provides a high growth reassortant influenza A virus having at least two gene segments of seasonal or pandemic strain origin, a PB1 gene segment of A/Texas/1/77 strain origin and a PA gene segment of A/Puerto Rico/8/34 (H1N1) origin coding for a PA protein comprising at least one amino acid modification at any one of positions 10, 275, 682, according to SEQ ID No. 1. Further provided are vaccine formulations comprising the reassortant influenza A virus of the invention.

High growth reassortant influenza A virus

Genetically engineered attenuated viruses

Growing community of inventors

Klosterneuburg, Austria

Michael Bergmann